Resveratrol and derivatives for the treatment of atrial fibrillation

被引:23
作者
Baczko, Istvan [1 ]
Light, Peter E. [2 ]
机构
[1] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary
[2] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2E1, Canada
来源
RESVERATROL AND HEALTH | 2015年 / 1348卷
基金
匈牙利科学研究基金会; 加拿大健康研究院;
关键词
atrial fibrillation; resveratrol; ion channels; drug design; arrhythmias; HEART-FAILURE; RED WINE; VENTRICULAR-ARRHYTHMIAS; PRESSURE-OVERLOAD; RISK; BIOAVAILABILITY; CALCINEURIN; MORTALITY; PATHWAY; TARGETS;
D O I
10.1111/nyas.12843
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Resveratrol is a bioactive polyphenol, found in grapes, red wine, and peanuts, and has recently garnered much media and scientific attention for its diverse beneficial health effects as a nutritional supplement or nutraceutical. Of particular interest are the well-documented cardioprotective effects of resveratrol that are mediated by diverse mechanisms, including its antioxidant and vascular effects. However, it is now becoming clear that resveratrol may also exhibit direct effects on cardiac function and rhythm through modulation of signaling pathways that regulate cardiac remodeling and ion channel activity that controls cardiac excitability. Resveratrol may therefore possess antiarrhythmic properties that contribute to the cardiovascular benefits of resveratrol. Atrial fibrillation (AF) is the most common cardiac arrhythmia, although current therapies are suboptimal. Our laboratory has been studying resveratrol's effects on cardiac ion channels and remodeling pathways, and we initiated a drug development program aimed at generating novel resveratrol derivatives with improved efficacy against AF when compared to currently available therapeutics. This review therefore focuses on the effects of resveratrol and new derivatives on a variety of cardiac ion channels and molecular pathways that contribute to the development and maintenance of atrial fibrillation.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 71 条
[1]
Optimization of trans-Resveratrol bioavailability for human therapy [J].
Amiot, Marie Josephe ;
Romier, Beatrice ;
Thi-Mai Anh Dao ;
Fanciullino, Raphaelle ;
Ciccolini, Joseph ;
Burcelin, Remy ;
Pechere, Laurent ;
Emond, Claude ;
Savouret, Jean-Francois ;
Seree, Eric .
BIOCHIMIE, 2013, 95 (06) :1233-1238
[2]
Baczkó I, 2015, CURR PHARM DESIGN, V21, P1011
[3]
Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation [J].
Baczko, Istvan ;
Liknes, David ;
Yang, Wei ;
Hamming, Kevin C. ;
Searle, Gavin ;
Jaeger, Kristian ;
Husti, Zoltan ;
Juhasz, Viktor ;
Klausz, Gergely ;
Pap, Robert ;
Saghy, Laszlo ;
Varro, Andras ;
Dolinsky, Vernon ;
Wang, Shaohua ;
Rauniyar, Vivek ;
Hall, Dennis ;
Dyck, Jason R. B. ;
Light, Peter E. .
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) :92-106
[4]
Ischemic heart disease and alcohol-related causes of death: A view of the French paradox [J].
Balkau, B ;
Eschwege, F ;
Eschwege, E .
ANNALS OF EPIDEMIOLOGY, 1997, 7 (07) :490-497
[5]
Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[6]
INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[7]
Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes [J].
Biala, Agnieszka ;
Tauriainen, Eveliina ;
Siltanen, Antti ;
Shi, Jin ;
Merasto, Saara ;
Louhelainen, Marjut ;
Martonen, Essi ;
Finckenberg, Piet ;
Muller, Dominik N. ;
Mervaala, Eero .
BLOOD PRESSURE, 2010, 19 (03) :196-205
[8]
Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities [J].
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (19) :1360-1369
[9]
Efficacy and Safety of Vernakalant in Recent-Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta-Analysis [J].
Buccelletti, Francesco ;
Iacomini, Paolo ;
Botta, Gianfranco ;
Marsiliani, Davide ;
Carroccia, Annarita ;
Silveri, Nicolo Gentiloni ;
Franceschi, Francesco .
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (12) :1872-1878
[10]
Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation [J].
Bukowska, A ;
Lendeckel, U ;
Hirte, D ;
Wolke, C ;
Striggow, F ;
Röhnert, P ;
Huth, C ;
Klein, HU ;
Goette, A .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (03) :333-342